TY - JOUR T1 - Clinical Value of Using Serological Cytokeratins as Therapeutic Markers in Thoracic Malignancies JF - Anticancer Research JO - Anticancer Res SP - 3545 LP - 3553 VL - 27 IS - 5B AU - SIMON EKMAN AU - PETER ERIKSSON AU - STEFAN BERGSTRÖM AU - PETER JOHANSSON AU - HELENA GOIKE AU - JOACHIM GULLBO AU - ROGER HENRIKSSON AU - ANDERS LARSSON AU - MICHAEL BERGQVIST Y1 - 2007/09/01 UR - http://ar.iiarjournals.org/content/27/5B/3545.abstract N2 - In recent years, there has been an increasing awareness among physicians of the value of therapeutic interventions in patients suffering from lung cancer and mesothelioma. A search for an optimal approach using surgery, irradiation and chemotherapy in different settings of the tumour disease, including curatively aimed adjuvant chemotherapy after locoregional surgery or radiotherapy, has resulted in gradually improved survival rates. Still, early detection is crucial if there is to be a possibility of curing patients or prolonging life in cases of relapsed disease. Several studies have been initiated in which surrogate markers are evaluated in comparison to chest X-rays and computer tomography. The present review focuses on the predictive and prognostic value of using serological cytokeratins as tumour markers for patients suffering from thoracic malignancies. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -